Since the start of the Levothyrox caseL’French Association of Thyroid Patients is mobilizing to demand a return to the old formula. A first order of analyzes had made it possible to identify in the new formula heavy metal nanoparticles. This time, the Patient Association is having the levothyroxine content of a box compared by chromatography old formula and 2 boxes of new formula from different batches. This analysis reveals that in the new formula, “the content of levothyroxine, the only hormonally useful component of the drug, is seriously below current specifications”. An under-dosage which could explain the dysfunctions of the treatment.
The new formula also contains another molecule, dextrothyroxine, not indicated in its composition, and which could also explain the patient health concerns under Levothyrox. Its known side effects are indeed comparable to those experienced by patients: fatigue, dizziness, headaches, hair loss…
All of these analysis results were sent to the judge of the health department of the Tribunal de Grande-Instance of Marseille, in charge of instruction. The Patient Association has also challenged the government and the National Medicines Safety Agency (ANSM) with this question: “Is it possible not to invoke the “precautionary principle” if the quality of Levothyrox poses a problem?”
Read also :
Thyroid disorders: what drugs are available?
6 Symptoms That May Indicate Hypothyroidism
-1597155771.jpg "Levothyrox: extension of the old formula until the end of 2021")
